CA2334887C - Method and apparatus for producing platelet rich plasma and/or platelet concentrate - Google Patents
Method and apparatus for producing platelet rich plasma and/or platelet concentrate Download PDFInfo
- Publication number
- CA2334887C CA2334887C CA2334887A CA2334887A CA2334887C CA 2334887 C CA2334887 C CA 2334887C CA 2334887 A CA2334887 A CA 2334887A CA 2334887 A CA2334887 A CA 2334887A CA 2334887 C CA2334887 C CA 2334887C
- Authority
- CA
- Canada
- Prior art keywords
- chamber
- platelet
- centrifugation
- supernatant
- plasma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/029—Separating blood components present in distinct layers in a container, not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D21/00—Separation of suspended solid particles from liquids by sedimentation
- B01D21/26—Separation of sediment aided by centrifugal force or centripetal force
- B01D21/262—Separation of sediment aided by centrifugal force or centripetal force by using a centrifuge
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
- B04B—CENTRIFUGES
- B04B5/00—Other centrifuges
- B04B5/04—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers
- B04B5/0407—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers for liquids contained in receptacles
- B04B5/0414—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers for liquids contained in receptacles comprising test tubes
- B04B5/0421—Radial chamber apparatus for separating predominantly liquid mixtures, e.g. butyrometers for liquids contained in receptacles comprising test tubes pivotably mounted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0415—Plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0427—Platelets; Thrombocytes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2221/00—Applications of separation devices
- B01D2221/10—Separation devices for use in medical, pharmaceutical or laboratory applications, e.g. separating amalgam from dental treatment residues
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- External Artificial Organs (AREA)
- Centrifugal Separators (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Platelet rich plasma and/or platelet concentrate is prepared by placing whole blood in a first chamber (6) of a sterile processing disposable having two chambers (6, 8). The processing disposable is subjected to a first centrifugation to separate red blood cells (36), and the resulting platelet rich plasma supernatant (38) is decanted to the second chamber (8). The processing disposable is subjected to a second centrifugation to concentrate platelets. A volume of the platelet poor plasma supernatant in the second chamber (8) is removed, and the platelets are re-suspended in the remaining plasma. The second chamber (8) may contain anticoagulant (34) to preclude aggregation of the platelets.
Description
METHOD AND APPARATUS FOR PRODUCING
PLATELET RICH PLASMA AND/OR PLATELET
CONCENTRATE
TECHNICAL FIELD
This invention relates to the art of methods and apparatus for producing platelet rich plasma or a platelet concentrate. In particular, the invention relates to automated, highly efficient methods for separating platelets and plasma and for combining these in a selected proportion to provide platelet rich plasma or platelet concentrate of selected concentration.
BACKGROUND
Common methods for producing platelet rich plasma (PRP) involve a "gentle" centrifugation of whole blood. Platelet concentrate (PC) results from a second centrifugation of the PRP.
Blood is a physiological fluid, which comprises several components that can be separated. Other physiological fluids include, for example, serum, plasma, saliva, lymph, or the like.
The platelets in platelet rich plasma PRP or platelet concentrate (PC) posses granules that contain growth factors (e.g., PDGF, TGF-Li, and others), which aid in accelerating angiogenesis (wound healing) and osteogenesis (bone growth). PRP/PC, when combined with thrombin, may also be used adjunctively to control bleeding (hemostasis), seal wounds, and as a vehicle for the delivery of drugs and/or biological agents. Further, the handling characteristics of certain organic materials, such as bone powder, can be greatly improved by combining them with PRP/PC, with or without the addition of thrombin. Such a combination also provides more secure placement of organic materials, for example, into an orthopedic defect. Some properties of la PRP/PC and thrombin (e.g., hemostasis and wound sealing) are similar to those of fibrin glue, except that fibrin glue has a greater adhesive property because of its concentration of fibrinogen above baseline levels.
A typical method of producing PC involves subjecting whole blood collected in a blood bag system to centrifugation to separate PRP from red blood cells. Then, the PRP is expressed from the first bag to a second bag and again subjected to centrifugation, which results in a concentration ("pellet") of platelets (PC) and a supernatant of platelet poor plasma (PPP).
The majority of the PPP is expressed to a third bag, leaving the concentrated platelets and a small proportion of PPP behind in the second bag, which is used for re-suspending the concentrated platelets. This method, with a typical platelet recovery efficiency of only 45%, is too cumbersome for point-of-care use and, as a result, does not lend itself to point-of-care production of autologous blood products.
One automated system for the production of autologous fibrinogen from plasma is known from US Patent 5,707,331 (Wells). That patent teaches a system for automated processing of whole blood by centrifugation into a plasma component that is further processed by physiochemical precipitation and further centrifugation into a fibrinogen component. The fibrinogen is recovered and provides a fibrin sealant when combined with thrombin.
The ability to produce PRP/PC on demand from small amounts of whole blood would greatly facilitate clinical utility of PRP/PC, and availability of autologous PRP/PC would eliminate the need for homologous PRP/PC, which may carry the risk of transmitting human disease. Further, it is often desirable to provide PRP/PC of a selected concentration to achieve a particular therapeutic outcome. However, the known methods presently used for producing PRP/PC are time consuming, inefficient, and do not lend themselves to production from small amounts of whole blood.
Accordingly, it is an object of this invention to provide a method and apparatus for processing efficiently small volumes of whole blood into PRP or PC of any selected concentration on demand, at the point of care, and in the clinical setting.
SUMMARY OF THE INVENTION
In accordance with the invention, small amounts of PRP or PC are easily produced by an automated method preferably carried out by a centrifuge such as that shown in US Patent 5,707,331 (Wells). The centrifuge shown in the `331 Wells patent receives a disposable container, or processing disposable (PD), having two chambers, and in the method of the present invention, whole blood is first placed in one chamber of the PD. The centrifuge is then operated to cause the red blood cells to sediment to the bottom of one chamber resulting in a supernatant of PRP. The centrifugation is stopped/reduced causing the PRP to drain to the second chamber, either by gravity or by centrifugal transfer.
PRP in the second chamber is then centrifuged a second time by restarting/accelerating the centrifuge. The centrifuge is then stopped, resulting in: (1) red blood cells in the one chamber, (2) platelets (PC) at the bottom of the second chamber, and (3) platelet poor plasma (PPP) as the supernatant in the second chamber. The foregoing operation of the centrifuge is preferably automated.
PLATELET RICH PLASMA AND/OR PLATELET
CONCENTRATE
TECHNICAL FIELD
This invention relates to the art of methods and apparatus for producing platelet rich plasma or a platelet concentrate. In particular, the invention relates to automated, highly efficient methods for separating platelets and plasma and for combining these in a selected proportion to provide platelet rich plasma or platelet concentrate of selected concentration.
BACKGROUND
Common methods for producing platelet rich plasma (PRP) involve a "gentle" centrifugation of whole blood. Platelet concentrate (PC) results from a second centrifugation of the PRP.
Blood is a physiological fluid, which comprises several components that can be separated. Other physiological fluids include, for example, serum, plasma, saliva, lymph, or the like.
The platelets in platelet rich plasma PRP or platelet concentrate (PC) posses granules that contain growth factors (e.g., PDGF, TGF-Li, and others), which aid in accelerating angiogenesis (wound healing) and osteogenesis (bone growth). PRP/PC, when combined with thrombin, may also be used adjunctively to control bleeding (hemostasis), seal wounds, and as a vehicle for the delivery of drugs and/or biological agents. Further, the handling characteristics of certain organic materials, such as bone powder, can be greatly improved by combining them with PRP/PC, with or without the addition of thrombin. Such a combination also provides more secure placement of organic materials, for example, into an orthopedic defect. Some properties of la PRP/PC and thrombin (e.g., hemostasis and wound sealing) are similar to those of fibrin glue, except that fibrin glue has a greater adhesive property because of its concentration of fibrinogen above baseline levels.
A typical method of producing PC involves subjecting whole blood collected in a blood bag system to centrifugation to separate PRP from red blood cells. Then, the PRP is expressed from the first bag to a second bag and again subjected to centrifugation, which results in a concentration ("pellet") of platelets (PC) and a supernatant of platelet poor plasma (PPP).
The majority of the PPP is expressed to a third bag, leaving the concentrated platelets and a small proportion of PPP behind in the second bag, which is used for re-suspending the concentrated platelets. This method, with a typical platelet recovery efficiency of only 45%, is too cumbersome for point-of-care use and, as a result, does not lend itself to point-of-care production of autologous blood products.
One automated system for the production of autologous fibrinogen from plasma is known from US Patent 5,707,331 (Wells). That patent teaches a system for automated processing of whole blood by centrifugation into a plasma component that is further processed by physiochemical precipitation and further centrifugation into a fibrinogen component. The fibrinogen is recovered and provides a fibrin sealant when combined with thrombin.
The ability to produce PRP/PC on demand from small amounts of whole blood would greatly facilitate clinical utility of PRP/PC, and availability of autologous PRP/PC would eliminate the need for homologous PRP/PC, which may carry the risk of transmitting human disease. Further, it is often desirable to provide PRP/PC of a selected concentration to achieve a particular therapeutic outcome. However, the known methods presently used for producing PRP/PC are time consuming, inefficient, and do not lend themselves to production from small amounts of whole blood.
Accordingly, it is an object of this invention to provide a method and apparatus for processing efficiently small volumes of whole blood into PRP or PC of any selected concentration on demand, at the point of care, and in the clinical setting.
SUMMARY OF THE INVENTION
In accordance with the invention, small amounts of PRP or PC are easily produced by an automated method preferably carried out by a centrifuge such as that shown in US Patent 5,707,331 (Wells). The centrifuge shown in the `331 Wells patent receives a disposable container, or processing disposable (PD), having two chambers, and in the method of the present invention, whole blood is first placed in one chamber of the PD. The centrifuge is then operated to cause the red blood cells to sediment to the bottom of one chamber resulting in a supernatant of PRP. The centrifugation is stopped/reduced causing the PRP to drain to the second chamber, either by gravity or by centrifugal transfer.
PRP in the second chamber is then centrifuged a second time by restarting/accelerating the centrifuge. The centrifuge is then stopped, resulting in: (1) red blood cells in the one chamber, (2) platelets (PC) at the bottom of the second chamber, and (3) platelet poor plasma (PPP) as the supernatant in the second chamber. The foregoing operation of the centrifuge is preferably automated.
The operator may then produce PRP/PC of a desired concentration by obtaining a prescribed volume of the plasma supernatant and re-suspending the platelets.
In a preferred embodiment, the operator inserts a blunt cannula attached to a syringe into the second chamber and withdraws a desired volume of plasma, which leaves behind a known volume of plasma. A second blunt cannula attached to a syringe is then inserted into the second chamber where the remaining known volume of plasma is used to re-suspend and recover the PRP/PC having increased platelet concentration.
There may be other ways to recover the platelets and plasma. For example, after completion of the automated steps, the operator could decant plasma from the second chamber by tilting the disposable container to cause an amount of plasma to return to the first chamber, leaving the desired amount of plasma in the second chamber. The remaining plasma and the platelets would then be mixed and recovered.
In one example, a patient's whole blood sample is obtained, containing a typical platelet count of 220 x 103/pl. Based on a typical platelet recovery efficiency of 60% and processing a typical blood volume of 50m1, re-suspending the PC in 5m1 of PPP will provide PRP with a platelet concentration of 1,320 x 103/pl, a six-fold increase in the platelet concentration.
Thus, according to the present invention, there is provided a method for producing a physiological fluid of selected composition comprising the steps of:
placing a physiological fluid having a plurality of components in a first chamber of a sterile container of a defined volume having horizontally spaced first and second chambers; subjecting said physiological fluid to centrifugation to separate at least one of said components from a more dense first supernatant;
decanting said first supernatant to said second chamber; subjecting said first supernatant to centrifugation to separate a second of said components from a second supernatant; removing a predetermined amount of said second supernatant from said second chamber whereby a remainder of said second supernatant is in said second chamber; and re-suspending said second of said components in said remainder of said second supernatant in said second chamber.
According to another aspect of the present invention, there is provided a method for making platelet rich plasma of increased concentration at point of care comprising the steps of placing blood in a first chamber of a sterile container having first and second chambers, wherein at least said second chamber is of a defined volume, subjecting said container and blood to centrifugation to provide a supernatant comprising platelet rich plasma, transferring said platelet rich plasma from said first chamber to said second chamber, subjecting said platelet rich plasma to centrifugation to provide separated platelets and platelet poor plasma, removing a portion of said platelet poor plasma from said second chamber and leaving a remaining portion of said platelet poor plasma and said separated platelets in said second chamber, and suspending said separated platelets in said remaining portion of said platelet poor plasma to obtain said platelet rich plasma of increased concentration.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates a disposable processing tube and centrifuge in accordance with the invention.
4a Figure 2 is a side view of the processing tube shown in figure 1, partly in vertical cross section.
Figures 3a through 3f are schematic cross sections of the processing tube of figure 2 showing the various orientations of the processing tube during operation of the centrifuge in accordance with the invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
Figure 1 schematically illustrates a centrifuge system 2 and a processing disposable (PD) 4 in accordance with the invention. The preferred centrifuge is that described in United States Patent 5,707,331 (Wells) programmed to operate as will be described in connection with figure 3. As will be appreciated, the rotor of the centrifuge 2 is designed to accept one or more PDs 4 simultaneously. In the preferred embodiment, the centrifuge accepts one or two PDs. A counterweight is placed opposite a filled PD when only one is used.
The PD used in accordance with the invention and shown in figure 2 is that shown in the noted `331 patent. This PD is preferably made of molded plastic and includes at least two chambers 6, 8. The two chambers are connected by a bridge 10, which connects the two chambers, preferably, at their tops. The chambers are closed by a lid 12, which maintains sterility of the fluid paths.
The lid includes extensions 18 and 20 having respective openings 22 and 24 for permitting access to the interior of the chambers. Chamber 6 includes a shelf 26 for assisting in the separation of PRP from cellular components, as will be described in more detail below. Chamber 6 also includes a hollow tube 28, which extends from the opening 22 through the shelf 26 to facilitate insertion of fluids into the chamber 6. The perimeter of the shelf allows plasma below the shelf 26 to flow upward.
Referring now to figures 3a through 3f, the operation of the centrifuge 2 in accordance with the process of the invention will be described. In the first step of the process, chamber 6 of the PD 4 is provided with a measured quantity of a physiological fluid 32 to be processed, such as whole human blood. A quantity (e.g., 1-5mI and preferably 2m1) of anticoagulant 34, preferably ACD-A, is added to chamber 8. Then, the PD is subjected to centrifugation as illustrated in figure 3b. This separates heavier components of the physiological fluids, such as red blood cells 36, from the supernatant, such as PRP 38. The ACD-A 34 remains in chamber 8.
The first centrifugation illustrated in figure 3b causes the red blood cells to separate from the PRP but does not significantly separate platelets from the remainder of the plasma. In the preferred embodiment, this first centrifugation is done at about 1200G (approximately 3600RPM) for a period of about two minutes.
For clarity figures 3a through 3f do not illustrate the shelf 26, but it should be noted that in the preferred embodiment, the shelf is located as close as possible to the boundary between the separated components, namely the red blood cells 36 and the plasma 38. The preferred method for accomplishing this is to determine the concentration of red blood cells in the patient's blood (i.e., the hematocrit) and to provide a quantity of blood that will fill the volume below the shelf with the red blood cells. Preferably, the chamber 6 is designed to accept 50ml of patient's blood as the nominal volume. This amount is adjusted during operation of the equipment in accordance with the hematocrit, and applicants have found that the volume of whole blood required will be in the range of 40m1-60m1.
After the red blood cells have been centrifugally separated, the PD is locked in the gravity drain position shown in figure 3c. This is described further in the `311 Wells patent and is preferably done by electrical activation of a magnet that moves a locking plate into engagement with a holder having the PD therein. When the PD is in this position, the PRP 38 in chamber 6 drains into the chamber 8 by gravity. For example, 25 ml of PRP is transferred to chamber 8. The PRP 38 also mixes with the ACD-A 34, previously in chamber 8, as it flows into the chamber through the flow channel 16.
It is often desirable during the draining step shown in figure 3c to continue rotation of the rotor at a slow speed, e.g., 60RPM, to provide a slight centrifugal force to ensure retention of the red blood cells 36 in the chamber 6.
As illustrated in figure 3d, the centrifuge is then accelerated again to subject the PRP 38 to centrifugation. The second centrifugation separates platelets 40 from the PPP supernatant 42. In the preferred embodiment, the second centrifugation is at about 1000G (approximately 3000RPM) for a period of about eight minutes.
It will be appreciated that the specific rotation rates for the first and second centrifugation steps can be varied. For example, the second centrifugation can be a hard spin. Also, the disclosed preferred rates are for a centrifuge having a maximum rotor radius of four inches (i.e., the radius of rotation measured from the axis to the bottom of the chamber). Centrifuges with other dimensions will require different rotation rates.
The ACD-A is provided in the chamber 8 for minimizing platelet aggregation. It has been found that the presence of an anticoagulant in the second chamber reduces aggregation of the platelets, thus shortening the overall time required for processing.
The next step in the process of the invention is shown in figure 3e. In this step, the centrifugation has been stopped, and the PD is allowed to assume an upright orientation, with the red blood cells 36 remaining in chamber 6, the platelets 40 at the bottom of chamber 8, and the PPP 42 as the supernatant in chamber 8. A hypodermic syringe 44 with a blunt cannula 46 is used for removing a predetermined amount of PPP. This is accomplished by inserting the blunt cannula through the opening 24 to a predetermined depth. The operator may determine that depth manually, or, as shown in figure 3e, a height adjusting guide 48 may be provided over the cannula to stop insertion at the desired depth. The guide may take any of several forms, the preferred form being a hollow tube that fits over the cannula and engages the bottom of the syringe. Also, a kit having a plurality of such guides of different lengths may be provided for allowing the operator to select one for withdrawal of different, predetermined amounts of PPP.
It will be appreciated that the described use of cannula 46 with height adjusting guide 48 removes from the chamber 8 a predetermined amount of fluid that in this case is equal to the difference between the volume of fluid in the chamber initially and the desired volume of fluid as defined by the height of the guide 48.
ts Further, removal of a desired amount of PPP may be accomplished by decanting some of the plasma back to chamber 6, either manually or by centrifugal transfer using the multiple-decanting features of the centrifuge described in the '331 Wells patent.
8a Continuing with the process shown in figure 3e, the syringe is operated after insertion of the cannula 46 to the desired depth to withdraw the desired amount of PPP, which is then used for other purposes, such as hemostasis.
As shown in figure 3f, the platelets 40 are then re-suspended in the remaining PPP to result in PRP/PC 50 with a desired platelet concentration that is several times higher than was the original supernatant 38. This PRP/PC of increased concentration is then used for any of a variety of purposes as are known in the art.
Modifications within the scope of the appended claims will be apparent to those of skill in the art.
In a preferred embodiment, the operator inserts a blunt cannula attached to a syringe into the second chamber and withdraws a desired volume of plasma, which leaves behind a known volume of plasma. A second blunt cannula attached to a syringe is then inserted into the second chamber where the remaining known volume of plasma is used to re-suspend and recover the PRP/PC having increased platelet concentration.
There may be other ways to recover the platelets and plasma. For example, after completion of the automated steps, the operator could decant plasma from the second chamber by tilting the disposable container to cause an amount of plasma to return to the first chamber, leaving the desired amount of plasma in the second chamber. The remaining plasma and the platelets would then be mixed and recovered.
In one example, a patient's whole blood sample is obtained, containing a typical platelet count of 220 x 103/pl. Based on a typical platelet recovery efficiency of 60% and processing a typical blood volume of 50m1, re-suspending the PC in 5m1 of PPP will provide PRP with a platelet concentration of 1,320 x 103/pl, a six-fold increase in the platelet concentration.
Thus, according to the present invention, there is provided a method for producing a physiological fluid of selected composition comprising the steps of:
placing a physiological fluid having a plurality of components in a first chamber of a sterile container of a defined volume having horizontally spaced first and second chambers; subjecting said physiological fluid to centrifugation to separate at least one of said components from a more dense first supernatant;
decanting said first supernatant to said second chamber; subjecting said first supernatant to centrifugation to separate a second of said components from a second supernatant; removing a predetermined amount of said second supernatant from said second chamber whereby a remainder of said second supernatant is in said second chamber; and re-suspending said second of said components in said remainder of said second supernatant in said second chamber.
According to another aspect of the present invention, there is provided a method for making platelet rich plasma of increased concentration at point of care comprising the steps of placing blood in a first chamber of a sterile container having first and second chambers, wherein at least said second chamber is of a defined volume, subjecting said container and blood to centrifugation to provide a supernatant comprising platelet rich plasma, transferring said platelet rich plasma from said first chamber to said second chamber, subjecting said platelet rich plasma to centrifugation to provide separated platelets and platelet poor plasma, removing a portion of said platelet poor plasma from said second chamber and leaving a remaining portion of said platelet poor plasma and said separated platelets in said second chamber, and suspending said separated platelets in said remaining portion of said platelet poor plasma to obtain said platelet rich plasma of increased concentration.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates a disposable processing tube and centrifuge in accordance with the invention.
4a Figure 2 is a side view of the processing tube shown in figure 1, partly in vertical cross section.
Figures 3a through 3f are schematic cross sections of the processing tube of figure 2 showing the various orientations of the processing tube during operation of the centrifuge in accordance with the invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
Figure 1 schematically illustrates a centrifuge system 2 and a processing disposable (PD) 4 in accordance with the invention. The preferred centrifuge is that described in United States Patent 5,707,331 (Wells) programmed to operate as will be described in connection with figure 3. As will be appreciated, the rotor of the centrifuge 2 is designed to accept one or more PDs 4 simultaneously. In the preferred embodiment, the centrifuge accepts one or two PDs. A counterweight is placed opposite a filled PD when only one is used.
The PD used in accordance with the invention and shown in figure 2 is that shown in the noted `331 patent. This PD is preferably made of molded plastic and includes at least two chambers 6, 8. The two chambers are connected by a bridge 10, which connects the two chambers, preferably, at their tops. The chambers are closed by a lid 12, which maintains sterility of the fluid paths.
The lid includes extensions 18 and 20 having respective openings 22 and 24 for permitting access to the interior of the chambers. Chamber 6 includes a shelf 26 for assisting in the separation of PRP from cellular components, as will be described in more detail below. Chamber 6 also includes a hollow tube 28, which extends from the opening 22 through the shelf 26 to facilitate insertion of fluids into the chamber 6. The perimeter of the shelf allows plasma below the shelf 26 to flow upward.
Referring now to figures 3a through 3f, the operation of the centrifuge 2 in accordance with the process of the invention will be described. In the first step of the process, chamber 6 of the PD 4 is provided with a measured quantity of a physiological fluid 32 to be processed, such as whole human blood. A quantity (e.g., 1-5mI and preferably 2m1) of anticoagulant 34, preferably ACD-A, is added to chamber 8. Then, the PD is subjected to centrifugation as illustrated in figure 3b. This separates heavier components of the physiological fluids, such as red blood cells 36, from the supernatant, such as PRP 38. The ACD-A 34 remains in chamber 8.
The first centrifugation illustrated in figure 3b causes the red blood cells to separate from the PRP but does not significantly separate platelets from the remainder of the plasma. In the preferred embodiment, this first centrifugation is done at about 1200G (approximately 3600RPM) for a period of about two minutes.
For clarity figures 3a through 3f do not illustrate the shelf 26, but it should be noted that in the preferred embodiment, the shelf is located as close as possible to the boundary between the separated components, namely the red blood cells 36 and the plasma 38. The preferred method for accomplishing this is to determine the concentration of red blood cells in the patient's blood (i.e., the hematocrit) and to provide a quantity of blood that will fill the volume below the shelf with the red blood cells. Preferably, the chamber 6 is designed to accept 50ml of patient's blood as the nominal volume. This amount is adjusted during operation of the equipment in accordance with the hematocrit, and applicants have found that the volume of whole blood required will be in the range of 40m1-60m1.
After the red blood cells have been centrifugally separated, the PD is locked in the gravity drain position shown in figure 3c. This is described further in the `311 Wells patent and is preferably done by electrical activation of a magnet that moves a locking plate into engagement with a holder having the PD therein. When the PD is in this position, the PRP 38 in chamber 6 drains into the chamber 8 by gravity. For example, 25 ml of PRP is transferred to chamber 8. The PRP 38 also mixes with the ACD-A 34, previously in chamber 8, as it flows into the chamber through the flow channel 16.
It is often desirable during the draining step shown in figure 3c to continue rotation of the rotor at a slow speed, e.g., 60RPM, to provide a slight centrifugal force to ensure retention of the red blood cells 36 in the chamber 6.
As illustrated in figure 3d, the centrifuge is then accelerated again to subject the PRP 38 to centrifugation. The second centrifugation separates platelets 40 from the PPP supernatant 42. In the preferred embodiment, the second centrifugation is at about 1000G (approximately 3000RPM) for a period of about eight minutes.
It will be appreciated that the specific rotation rates for the first and second centrifugation steps can be varied. For example, the second centrifugation can be a hard spin. Also, the disclosed preferred rates are for a centrifuge having a maximum rotor radius of four inches (i.e., the radius of rotation measured from the axis to the bottom of the chamber). Centrifuges with other dimensions will require different rotation rates.
The ACD-A is provided in the chamber 8 for minimizing platelet aggregation. It has been found that the presence of an anticoagulant in the second chamber reduces aggregation of the platelets, thus shortening the overall time required for processing.
The next step in the process of the invention is shown in figure 3e. In this step, the centrifugation has been stopped, and the PD is allowed to assume an upright orientation, with the red blood cells 36 remaining in chamber 6, the platelets 40 at the bottom of chamber 8, and the PPP 42 as the supernatant in chamber 8. A hypodermic syringe 44 with a blunt cannula 46 is used for removing a predetermined amount of PPP. This is accomplished by inserting the blunt cannula through the opening 24 to a predetermined depth. The operator may determine that depth manually, or, as shown in figure 3e, a height adjusting guide 48 may be provided over the cannula to stop insertion at the desired depth. The guide may take any of several forms, the preferred form being a hollow tube that fits over the cannula and engages the bottom of the syringe. Also, a kit having a plurality of such guides of different lengths may be provided for allowing the operator to select one for withdrawal of different, predetermined amounts of PPP.
It will be appreciated that the described use of cannula 46 with height adjusting guide 48 removes from the chamber 8 a predetermined amount of fluid that in this case is equal to the difference between the volume of fluid in the chamber initially and the desired volume of fluid as defined by the height of the guide 48.
ts Further, removal of a desired amount of PPP may be accomplished by decanting some of the plasma back to chamber 6, either manually or by centrifugal transfer using the multiple-decanting features of the centrifuge described in the '331 Wells patent.
8a Continuing with the process shown in figure 3e, the syringe is operated after insertion of the cannula 46 to the desired depth to withdraw the desired amount of PPP, which is then used for other purposes, such as hemostasis.
As shown in figure 3f, the platelets 40 are then re-suspended in the remaining PPP to result in PRP/PC 50 with a desired platelet concentration that is several times higher than was the original supernatant 38. This PRP/PC of increased concentration is then used for any of a variety of purposes as are known in the art.
Modifications within the scope of the appended claims will be apparent to those of skill in the art.
Claims (8)
1. A method for producing a physiological fluid of selected composition comprising the steps of:
placing a physiological fluid having a plurality of components in a first chamber of a sterile container of a defined volume having horizontally spaced first and second chambers;
subjecting said physiological fluid to centrifugation to separate at least one of said components from a more dense first supernatant;
decanting said first supernatant to said second chamber;
subjecting said first supernatant to centrifugation to separate a second of said components from a second supernatant;
removing a predetermined amount of said second supernatant from said second chamber whereby a remainder of said second supernatant is in said second chamber; and re-suspending said second of said components in said remainder of said second supernatant in said second chamber.
placing a physiological fluid having a plurality of components in a first chamber of a sterile container of a defined volume having horizontally spaced first and second chambers;
subjecting said physiological fluid to centrifugation to separate at least one of said components from a more dense first supernatant;
decanting said first supernatant to said second chamber;
subjecting said first supernatant to centrifugation to separate a second of said components from a second supernatant;
removing a predetermined amount of said second supernatant from said second chamber whereby a remainder of said second supernatant is in said second chamber; and re-suspending said second of said components in said remainder of said second supernatant in said second chamber.
2. A method according to claim 1 further comprising the step of placing anticoagulant in said second chamber.
3. A method according to claim 1 wherein said physiological fluid is blood.
4. A method according to claim 3 wherein said physiological fluid is platelet rich plasma and said step of subjecting said physiological fluid to centrifugation comprises subjecting blood to a first centrifugation for about two minutes.
5. A method according to claim 4 wherein said step of subjecting said first supernatant to centrifugation comprises subjecting platelet rich plasma to a second centrifugation for about eight minutes.
6. A method for making platelet rich plasma of increased concentration at point of care comprising the steps of placing blood in a first chamber of a sterile container having first and second chambers, wherein at least said second chamber is of a defined volume, subjecting said container and blood to centrifugation to provide a supernatant comprising platelet rich plasma, transferring said platelet rich plasma from said first chamber to said second chamber, subjecting said platelet rich plasma to centrifugation to provide separated platelets and platelet poor plasma, removing a portion of said platelet poor plasma from said second chamber and leaving a remaining portion of said platelet poor plasma and said separated platelets in said second chamber, and suspending said separated platelets in said remaining portion of said platelet poor plasma to obtain said platelet rich plasma of increased concentration.
7. A method according to claim 6 further comprising the step of placing an anticoagulant in said second chamber.
8. A method according to claim 6 wherein said step of removing comprises inserting a cannula into said second chamber and withdrawing said portion of platelet poor plasma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12880099P | 1999-04-12 | 1999-04-12 | |
US60/128,800 | 1999-04-12 | ||
PCT/US2000/008718 WO2000061256A1 (en) | 1999-04-12 | 2000-04-11 | Method and apparatus for producing platelet rich plasma and/or platelet concentrate |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2334887A1 CA2334887A1 (en) | 2000-10-19 |
CA2334887C true CA2334887C (en) | 2012-01-24 |
Family
ID=22437036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2334887A Expired - Fee Related CA2334887C (en) | 1999-04-12 | 2000-04-11 | Method and apparatus for producing platelet rich plasma and/or platelet concentrate |
Country Status (8)
Country | Link |
---|---|
US (1) | US6398972B1 (en) |
EP (1) | EP1093390B1 (en) |
JP (1) | JP4892133B2 (en) |
CN (1) | CN1238083C (en) |
CA (1) | CA2334887C (en) |
ES (1) | ES2424618T3 (en) |
HK (1) | HK1037987A1 (en) |
WO (1) | WO2000061256A1 (en) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6524231B1 (en) | 1999-09-03 | 2003-02-25 | Baxter International Inc. | Blood separation chamber with constricted interior channel and recessed passage |
US20020104808A1 (en) * | 2000-06-30 | 2002-08-08 | Lou Blasetti | Method and apparatus for producing platelet rich plasma and/or platelet concentrate |
US7011852B2 (en) * | 2001-05-07 | 2006-03-14 | Hemogenesis, Llc | Separation of platelets from whole blood for use as a healant |
US8101077B2 (en) * | 2001-05-07 | 2012-01-24 | Sivaprasad Sukavaneshvar | Device for separating platelets from fluid suspensions |
US7832566B2 (en) | 2002-05-24 | 2010-11-16 | Biomet Biologics, Llc | Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles |
US7992725B2 (en) | 2002-05-03 | 2011-08-09 | Biomet Biologics, Llc | Buoy suspension fractionation system |
US20030205538A1 (en) | 2002-05-03 | 2003-11-06 | Randel Dorian | Methods and apparatus for isolating platelets from blood |
US20060278588A1 (en) * | 2002-05-24 | 2006-12-14 | Woodell-May Jennifer E | Apparatus and method for separating and concentrating fluids containing multiple components |
WO2003099412A1 (en) | 2002-05-24 | 2003-12-04 | Biomet Manufacturing Corp. | Apparatus and method for separating and concentrating fluids containing multiple components |
US7845499B2 (en) | 2002-05-24 | 2010-12-07 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
ATE552909T1 (en) * | 2002-08-02 | 2012-04-15 | Harvest Technologies Corp | DECANTING CENTRIFUGE WITH VIBRATION ISOLATION |
US7297272B2 (en) * | 2002-10-24 | 2007-11-20 | Fenwal, Inc. | Separation apparatus and method |
CA2514474C (en) * | 2003-01-30 | 2014-05-06 | Avner Yayon | Freeze-dried fibrin matrices and methods for preparation thereof |
US7291450B2 (en) * | 2003-03-28 | 2007-11-06 | Smith & Nephew, Inc. | Preparation of a cell concentrate from a physiological solution |
US7067123B2 (en) | 2003-04-29 | 2006-06-27 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
EP1693675A4 (en) * | 2003-12-08 | 2013-09-18 | Wako Pure Chem Ind Ltd | Automatic analyzer-use reaction disc and separating cell |
US7354515B2 (en) | 2004-02-23 | 2008-04-08 | Millennium Medical Technologies, Inc. | Fluid concentrator |
US7335508B2 (en) * | 2004-07-22 | 2008-02-26 | Prochon Biotech Ltd. | Porous plasma protein matrices and methods for preparation thereof |
DE102004036840B4 (en) * | 2004-07-29 | 2012-04-19 | Orthogen Ag | Method and means for obtaining platelet rich plasma |
CA2579041A1 (en) * | 2004-09-07 | 2006-03-16 | Smith & Nephew, Inc. | Methods and devices for sterile field transfer |
US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
US20060094865A1 (en) * | 2004-10-29 | 2006-05-04 | Kapur Terri A | Intraoperative method for isolating and concentrating autologous growth factors and for forming residual autologous growth factor compositions |
WO2006058153A1 (en) * | 2004-11-23 | 2006-06-01 | Smith & Nephew, Inc. | Composite mixer |
ITRM20040638A1 (en) | 2004-12-24 | 2005-03-24 | Advance Holdings Ltd | SEMISINTETIC PIASTRINIC GEL AND METHOD FOR ITS PREPARATION. |
US7815926B2 (en) | 2005-07-11 | 2010-10-19 | Musculoskeletal Transplant Foundation | Implant for articular cartilage repair |
US20070036766A1 (en) * | 2005-08-09 | 2007-02-15 | Sherwin Kevy | Tissue graft composition comprising autologous bone marrow and purified autologous thrombin |
US7771590B2 (en) | 2005-08-23 | 2010-08-10 | Biomet Manufacturing Corp. | Method and apparatus for collecting biological materials |
US8048297B2 (en) | 2005-08-23 | 2011-11-01 | Biomet Biologics, Llc | Method and apparatus for collecting biological materials |
US8921109B2 (en) | 2005-09-19 | 2014-12-30 | Histogenics Corporation | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof |
WO2007061889A2 (en) * | 2005-11-17 | 2007-05-31 | Biomimetic Therapeutics, Inc. | Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
CA2641860C (en) | 2006-02-09 | 2015-07-14 | Biomimetic Therapeutics, Inc. | Compositions and methods for treating bone |
US8567609B2 (en) | 2006-05-25 | 2013-10-29 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
ES2324438B1 (en) * | 2006-06-19 | 2010-05-25 | Lorente Alvarez-Beigbeder, S.L. | METHOD FOR OBTAINING PLATES. |
US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
JP5484047B2 (en) | 2006-06-30 | 2014-05-07 | バイオミメティック セラピューティクス, エルエルシー | PDGF-biomatrix composition and method for treating rotator cuff injury |
US8106008B2 (en) | 2006-11-03 | 2012-01-31 | Biomimetic Therapeutics, Inc. | Compositions and methods for arthrodetic procedures |
US20080195476A1 (en) * | 2007-02-09 | 2008-08-14 | Marchese Michael A | Abandonment remarketing system |
WO2008100442A1 (en) * | 2007-02-09 | 2008-08-21 | Biomet Biologics, Inc. | Treatment of tissue defects with a therapeutic composition |
JP2008231095A (en) | 2007-02-16 | 2008-10-02 | Harvest Technologies Corp | Method for adjusting sedimentation rate |
US8034014B2 (en) | 2007-03-06 | 2011-10-11 | Biomet Biologics, Llc | Angiogenesis initation and growth |
US8435551B2 (en) | 2007-03-06 | 2013-05-07 | Musculoskeletal Transplant Foundation | Cancellous construct with support ring for repair of osteochondral defects |
US8328024B2 (en) | 2007-04-12 | 2012-12-11 | Hanuman, Llc | Buoy suspension fractionation system |
WO2008127639A1 (en) | 2007-04-12 | 2008-10-23 | Biomet Biologics, Llc | Buoy suspension fractionation system |
US20080269762A1 (en) * | 2007-04-25 | 2008-10-30 | Biomet Manufacturing Corp. | Method and device for repair of cartilage defects |
US7901344B2 (en) * | 2007-05-11 | 2011-03-08 | Biomet Biologics, Llc | Methods of reducing surgical complications in cancer patients |
WO2009073232A1 (en) * | 2007-12-07 | 2009-06-11 | Harvest Technologies Corporation | Floating disk for separating blood components |
US20090192528A1 (en) * | 2008-01-29 | 2009-07-30 | Biomet Biologics, Inc. | Method and device for hernia repair |
CN102014977B (en) | 2008-02-07 | 2015-09-02 | 生物模拟治疗有限责任公司 | For compositions and the method for Distraction Osteogenesis |
US8075468B2 (en) | 2008-02-27 | 2011-12-13 | Fenwal, Inc. | Systems and methods for mid-processing calculation of blood composition |
PL2259774T3 (en) | 2008-02-27 | 2013-04-30 | Biomet Biologics Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
US8753690B2 (en) | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
US8685258B2 (en) | 2008-02-27 | 2014-04-01 | Fenwal, Inc. | Systems and methods for conveying multiple blood components to a recipient |
WO2009111338A1 (en) | 2008-02-29 | 2009-09-11 | Biomet Manufacturing Corp. | A system and process for separating a material |
WO2009111069A1 (en) | 2008-03-05 | 2009-09-11 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
AU2009291828C1 (en) * | 2008-09-09 | 2016-03-17 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
US8309343B2 (en) | 2008-12-01 | 2012-11-13 | Baxter International Inc. | Apparatus and method for processing biological material |
US8177072B2 (en) * | 2008-12-04 | 2012-05-15 | Thermogenesis Corp. | Apparatus and method for separating and isolating components of a biological fluid |
CN102341112B (en) | 2009-02-05 | 2014-01-29 | 皮埃尔·菲利帕尔 | Method and means for producing tissues and tissues obtained |
JP2012519556A (en) * | 2009-03-05 | 2012-08-30 | バイオミメティック セラピューティクス, インコーポレイテッド | Platelet-derived growth factor compositions and methods for treating osteochondral defects |
US8187475B2 (en) | 2009-03-06 | 2012-05-29 | Biomet Biologics, Llc | Method and apparatus for producing autologous thrombin |
US8834402B2 (en) * | 2009-03-12 | 2014-09-16 | Haemonetics Corporation | System and method for the re-anticoagulation of platelet rich plasma |
US8313954B2 (en) | 2009-04-03 | 2012-11-20 | Biomet Biologics, Llc | All-in-one means of separating blood components |
AU2010237191A1 (en) | 2009-04-07 | 2011-11-03 | Velin-Pharma A/S | Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system |
US9011800B2 (en) | 2009-07-16 | 2015-04-21 | Biomet Biologics, Llc | Method and apparatus for separating biological materials |
US20110052561A1 (en) * | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
CA2772084C (en) | 2009-08-27 | 2016-10-18 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
CN102573856B (en) | 2009-09-10 | 2016-10-26 | 弗莱明·韦林 | For preparation method and the therapeutic application thereof of Microrna |
JP6144049B2 (en) | 2010-02-22 | 2017-06-07 | バイオミメティック セラピューティクス,リミテッド ライアビリティ カンパニー | Platelet-derived growth factor compositions and methods for treating tendon disorders |
US8591391B2 (en) | 2010-04-12 | 2013-11-26 | Biomet Biologics, Llc | Method and apparatus for separating a material |
EP2611456A2 (en) | 2010-09-03 | 2013-07-10 | Biomet Biologics, LLC | Methods and compositions for delivering interleukin-1 receptor antagonist |
US9555171B2 (en) | 2010-09-30 | 2017-01-31 | Depuy Mitek, Llc | Methods and devices for collecting separate components of whole blood |
US8394006B2 (en) | 2010-11-19 | 2013-03-12 | Kensey Nash Corporation | Centrifuge |
US8469871B2 (en) | 2010-11-19 | 2013-06-25 | Kensey Nash Corporation | Centrifuge |
US8556794B2 (en) | 2010-11-19 | 2013-10-15 | Kensey Nash Corporation | Centrifuge |
US8870733B2 (en) | 2010-11-19 | 2014-10-28 | Kensey Nash Corporation | Centrifuge |
US8317672B2 (en) | 2010-11-19 | 2012-11-27 | Kensey Nash Corporation | Centrifuge method and apparatus |
US20120213754A1 (en) * | 2011-02-23 | 2012-08-23 | Stem Cell Partners Llc | Method of Preconditioning of Cell Suspensions |
US9011684B2 (en) | 2011-03-07 | 2015-04-21 | Spinesmith Holdings, Llc | Fluid concentrator with removable cartridge |
US9164079B2 (en) | 2011-03-17 | 2015-10-20 | Greyledge Technologies Llc | Systems for autologous biological therapeutics |
US9011846B2 (en) | 2011-05-02 | 2015-04-21 | Biomet Biologics, Llc | Thrombin isolated from blood and blood fractions |
DE102011105311A1 (en) * | 2011-06-19 | 2012-12-20 | Walter Pobitschka | Separation procedure for blood, separation vessel for a blood centrifuge, system for filling a freezing container |
US8852446B2 (en) | 2011-10-03 | 2014-10-07 | Palo Alto Research Center Incorporated | Platelet extraction from blood |
KR101197908B1 (en) * | 2011-10-31 | 2012-11-05 | 박현정 | A container for centrifugal separation |
KR101197974B1 (en) * | 2011-11-01 | 2012-11-05 | 박현정 | A container for centrifugal separator capable of rapid centrifugal separation |
EP2806914B1 (en) | 2012-01-23 | 2021-09-22 | Estar Technologies Ltd | A system and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma(prp) |
AU2013219890A1 (en) | 2012-02-15 | 2014-10-02 | Microaire Surgical Instruments, Llc | Apparatus for centrifugation and methods therefore |
US20150355191A1 (en) | 2012-07-11 | 2015-12-10 | Biomimetic Therapeutics, Llc | Cell-Based Assay for Neutralizing Antibodies |
CN102755770B (en) * | 2012-07-30 | 2014-12-03 | 博雅干细胞科技有限公司 | Extraction method of platelet rich plasma (PRP) and extracted PRP |
US9642956B2 (en) | 2012-08-27 | 2017-05-09 | Biomet Biologics, Llc | Apparatus and method for separating and concentrating fluids containing multiple components |
US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
WO2015021189A1 (en) | 2013-08-06 | 2015-02-12 | Regenerative Sciences, Llc | Bone marrow adipose portion isolation device and methods |
WO2015081253A1 (en) | 2013-11-26 | 2015-06-04 | Biomet Biologics, Llc | Methods of mediating macrophage phenotypes |
CA2937486A1 (en) * | 2014-01-20 | 2015-07-23 | Halcyon Biomedical, Incorporated | Passive separation of whole blood |
CA2938268A1 (en) | 2014-01-31 | 2015-08-06 | Dsm Ip Assets B.V. | Adipose tissue processing centrifuge and methods of use |
EP3212332B1 (en) | 2014-10-28 | 2021-02-24 | Arteriocyte Medical Systems, Inc. | Centrifuge tube comprising a floating buoy, and methods for using the same |
US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
CN104771762A (en) * | 2015-03-23 | 2015-07-15 | 南京大学医学院附属鼓楼医院 | Preparation method of antitumor drug carrying platelet drug loading system |
WO2017015517A1 (en) * | 2015-07-21 | 2017-01-26 | Theranos, Inc. | Systems, devices, and methods for bodily fluid sample collection, transport, and handling |
US10272445B2 (en) | 2015-11-24 | 2019-04-30 | Royal Biologics | Methods and apparatus for separating fluid components |
KR101894966B1 (en) * | 2017-03-30 | 2018-09-04 | 신현순 | A container for centrifugal separator |
CN110944616A (en) * | 2017-07-22 | 2020-03-31 | 艾哈迈德·甘巴里 | PRP production kit with the ability to separate PRP from blood and then infuse the remaining elements |
US10624615B2 (en) | 2017-10-06 | 2020-04-21 | Stephen S Ho | Apparatus and method for collecting and isolating cells |
EP3470142A1 (en) | 2017-10-11 | 2019-04-17 | Orthogen AG | Device comprising a first chamber for receiving a body fluid |
US20220088589A1 (en) | 2019-01-21 | 2022-03-24 | Eclipse Medcorp, Llc | Methods, Systems and Apparatus for Separating Components of a Biological Sample |
IT201900015707A1 (en) | 2019-09-05 | 2021-03-05 | Emotec Srl | "MEDICAL DEVICE AND APPARATUS FOR THE PRODUCTION, WITH CLOSED CIRCUIT, OF PLASMA RICH IN PLATES AND DERIVATIVES, FOR NON-TRANSFUSIONAL USE" |
CN114146827B (en) * | 2021-11-26 | 2024-01-23 | 南京双威生物医学科技有限公司 | One-time centrifugation preparation method of platelet-rich plasma |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA461698A (en) | 1949-12-13 | Langstadt Julius | Compartmented receptacle | |
US1722396A (en) | 1928-02-13 | 1929-07-30 | Winfield S Reiber | Milk bottle |
FR936560A (en) | 1946-11-21 | 1948-07-23 | Csf | Sealed oil tank for high voltage devices mounted on fighter planes |
US3190546A (en) | 1959-03-27 | 1965-06-22 | Raccuglia Giovanni | Method and apparatus for separating liquid mixtures |
US3420437A (en) | 1967-02-15 | 1969-01-07 | Sorvall Inc Ivan | Cell washing centrifuge |
US3586484A (en) | 1969-05-23 | 1971-06-22 | Atomic Energy Commission | Multistation analytical photometer and method of use |
US3642163A (en) | 1970-03-20 | 1972-02-15 | Lorrell C Mcfarland | Multitubular pressure tank |
US3605829A (en) | 1970-04-29 | 1971-09-20 | Becton Dickinson Co | Blood handling machine |
US3774455A (en) | 1971-12-22 | 1973-11-27 | D Seidler | Urine testing apparatus |
BE793544A (en) | 1972-01-31 | 1973-04-16 | American Hospital Supply Corp | CENTRIFUGE |
IT954219B (en) | 1972-04-21 | 1973-08-30 | Tomasello M | URINE CONTAINER INTENDED FOR ANALYSIS |
US3877634A (en) | 1973-05-25 | 1975-04-15 | Du Pont | Cell washing centrifuge apparatus and system |
US3851817A (en) | 1973-05-29 | 1974-12-03 | E Buck | Method and means for centrifuging chilled blood samples |
US3953172A (en) | 1974-05-10 | 1976-04-27 | Union Carbide Corporation | Method and apparatus for assaying liquid materials |
IT1028403B (en) | 1975-01-16 | 1979-01-30 | Crippa Egidia | CONTAINER WITH EXTERNAL TUBE FOR ANALYSIS OF URINE AND OTHER ACID LIQUIDS |
US3951334A (en) | 1975-07-07 | 1976-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for automatically positioning centrifuge tubes |
US4066407A (en) | 1976-12-16 | 1978-01-03 | Vincent Lupica | Body fluid testing system and process |
US4150089A (en) | 1977-09-06 | 1979-04-17 | Linet Michael S | Multi-chamber test tube |
US4146172A (en) * | 1977-10-18 | 1979-03-27 | Baxter Travenol Laboratories, Inc. | Centrifugal liquid processing system |
JPS5828529B2 (en) | 1978-11-03 | 1983-06-16 | 株式会社日本クリンエンジン研究所 | Portable constant volume ratio mixing container |
US4285463A (en) | 1979-11-01 | 1981-08-25 | American Hospital Supply Corporation | Decanting centrifuge |
US4431423A (en) | 1982-03-10 | 1984-02-14 | E. I. Du Pont De Nemours & Co. | Cell washing apparatus having radially inwardly directed retaining arms |
CA1216518A (en) | 1982-11-01 | 1987-01-13 | Gail A. Rock | Plasma-free medium for platelet storage |
US4695460A (en) * | 1986-03-19 | 1987-09-22 | American Red Cross | Synthetic, plasma-free, transfusible platelet storage medium |
US4714457A (en) | 1986-09-15 | 1987-12-22 | Robert Alterbaum | Method and apparatus for use in preparation of fibrinogen from a patient's blood |
AU617265B2 (en) | 1988-06-23 | 1991-11-21 | Asahi Medical Co. Ltd. | Method for separating blood into blood components, and blood components separator unit |
US4932546A (en) | 1989-03-16 | 1990-06-12 | Buttes Gas & Oil Co. | Pressure vessel |
US5045047A (en) | 1989-07-17 | 1991-09-03 | Zymark Corporation | Automated centrifuge |
US5318524A (en) | 1990-01-03 | 1994-06-07 | Cryolife, Inc. | Fibrin sealant delivery kit |
US5178602A (en) | 1990-02-07 | 1993-01-12 | Wells John R | Automatic decanting centrifuge |
US5047004A (en) | 1990-02-07 | 1991-09-10 | Wells John R | Automatic decanting centrifuge |
US5089146A (en) * | 1990-02-12 | 1992-02-18 | Miles Inc. | Pre-storage filtration of platelets |
US5209776A (en) | 1990-07-27 | 1993-05-11 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
US5292362A (en) | 1990-07-27 | 1994-03-08 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
US5447245A (en) | 1993-07-20 | 1995-09-05 | Merhar; Richard D. | Graduated proportioning and mixing container |
EP0666771B1 (en) * | 1993-07-26 | 2000-08-23 | Baxter International Inc. | Apparatus for separating blood components with controlled anticoagulant dosage |
JP3715338B2 (en) * | 1994-11-11 | 2005-11-09 | テルモ株式会社 | Blood component separator |
US5503284A (en) | 1994-12-23 | 1996-04-02 | Li; Hofman Y. | Single continuous wall, multi-chamber container |
US5707331A (en) | 1995-05-05 | 1998-01-13 | John R. Wells | Automatic multiple-decanting centrifuge |
-
2000
- 2000-04-11 ES ES00921588T patent/ES2424618T3/en not_active Expired - Lifetime
- 2000-04-11 CN CNB008005648A patent/CN1238083C/en not_active Expired - Fee Related
- 2000-04-11 CA CA2334887A patent/CA2334887C/en not_active Expired - Fee Related
- 2000-04-11 US US09/582,730 patent/US6398972B1/en not_active Expired - Lifetime
- 2000-04-11 EP EP00921588.0A patent/EP1093390B1/en not_active Expired - Lifetime
- 2000-04-11 WO PCT/US2000/008718 patent/WO2000061256A1/en active Application Filing
- 2000-04-11 JP JP2000610582A patent/JP4892133B2/en not_active Expired - Lifetime
-
2001
- 2001-12-20 HK HK01108948A patent/HK1037987A1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2002541225A (en) | 2002-12-03 |
ES2424618T3 (en) | 2013-10-07 |
CA2334887A1 (en) | 2000-10-19 |
HK1037987A1 (en) | 2002-03-01 |
EP1093390A4 (en) | 2009-03-04 |
EP1093390B1 (en) | 2013-05-08 |
CN1238083C (en) | 2006-01-25 |
WO2000061256A1 (en) | 2000-10-19 |
JP4892133B2 (en) | 2012-03-07 |
EP1093390A1 (en) | 2001-04-25 |
US6398972B1 (en) | 2002-06-04 |
CN1300233A (en) | 2001-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2334887C (en) | Method and apparatus for producing platelet rich plasma and/or platelet concentrate | |
US20140311988A1 (en) | Method and apparatus for producing platelet rich plasma and/or platelet concentrate | |
US8950586B2 (en) | Methods and apparatus for isolating platelets from blood | |
ES2780057T3 (en) | Method for the preparation of at least one compound from blood, and sampling devices to be used in the execution of said method | |
US20090202981A1 (en) | Triple spin, double pool and revolumization process for concentrating platelets and derivative platelet concentrate | |
CA2617465A1 (en) | Triple spin, double pool and revolumization process for concentrating platelets, and derivative platelet concentrate | |
EP2049223B1 (en) | Apparatus and method for preparing platelet rich plasma and concentrates thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20150413 |